[go: up one dir, main page]

RU2007137988A - VITAMIN MIXES - Google Patents

VITAMIN MIXES Download PDF

Info

Publication number
RU2007137988A
RU2007137988A RU2007137988/15A RU2007137988A RU2007137988A RU 2007137988 A RU2007137988 A RU 2007137988A RU 2007137988/15 A RU2007137988/15 A RU 2007137988/15A RU 2007137988 A RU2007137988 A RU 2007137988A RU 2007137988 A RU2007137988 A RU 2007137988A
Authority
RU
Russia
Prior art keywords
composition according
vitamin
composition
present
zinc
Prior art date
Application number
RU2007137988/15A
Other languages
Russian (ru)
Inventor
Вероник ЛЕВЕР (FR)
Вероник ЛЕВЕР
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2007137988A publication Critical patent/RU2007137988A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Композиция, содержащая ! примерно от 10 до 150 мг витамина С, ! примерно от 5 до 30 мг витамина Е, ! примерно от 1 до 20 мг лютеина, ! примерно от 5 до 30 мг цинка, ! примерно от 15 до 150 мкг селена, ! примерно от 5 до 75 мкг хрома и ! примерно от 10 до 600 мг омега-3-жирной кислоты. ! 2. Композиция по п.1, дополнительно содержащая примерно от 0,5 до 6 мг бета-каротина. ! 3. Композиция по пп.1 и 2, в которой витамин С присутствует в виде аскорбиновой кислоты, натрия аскорбата или их смеси. ! 4. Композиция по пп.1 и 2, в которой витамин Е присутствует в виде DL-альфа-токоферола ацетата. ! 5. Композиция по пп.1 и 2, в которой омега-3-жирная кислота присутствует в виде рыбьего жира, содержащего 33% ДГК и 23% ЭПК (в пересчете на общую массу рыбьего жира). ! 6. Композиция по п.1 или 2, которая имеет следующий состав: ! бета-каротин2 мг (3344 ME); (+/- 20%)аскорбиновая кислота60 мг; (+/- 20%)витамин Е10 мг (10 ME); (+/-20%)цинка глюконат15 мг; (+/-20%)натрия селенит50 мкг; (+/- 20%)гексагидрат хрома(III) трихлорида25 мкг; (+/- 20%)лютеин (чистый продукт Flora Glo)6 мг; (+/- 20%)рыбий жир (33% эйкозапентановой кислоты (ЭПК): 23%200 мг; (+/- 20%)докогексановой кислоты (ДГК))  ! где количества даны в виде мас.% в пересчете на общую массу композиции. ! 7. Композиция по п.6, из которой исключен бета-каротин. ! 8. Композиция по пп.1 и 2, в которой цинк присутствует в виде цинка оксида. ! 9. Композиция по одному из пп.1 и 2, которая входит в состав одной, двух, трех или большего количества таблеток. ! 10. Применение композиции по пп.1-9 для приготовления лекарственного средства, предназначенного для лечения и/или предупреждения связанной с возрастом дегенерации желтого пятна или любого другого патологического нарушения сетчатки. ! 11. Способ лечения и/или предупреж1. A composition comprising! from about 10 to 150 mg of vitamin C,! from about 5 to 30 mg of vitamin E,! approximately 1 to 20 mg of lutein,! from about 5 to 30 mg of zinc,! from about 15 to 150 micrograms of selenium,! from about 5 to 75 micrograms of chromium and! from about 10 to 600 mg of omega-3 fatty acid. ! 2. The composition according to claim 1, additionally containing from about 0.5 to 6 mg beta-carotene. ! 3. The composition according to claims 1 and 2, in which vitamin C is present in the form of ascorbic acid, sodium ascorbate, or a mixture thereof. ! 4. The composition according to claims 1 and 2, in which vitamin E is present in the form of DL-alpha-tocopherol acetate. ! 5. The composition according to claims 1 and 2, in which the omega-3 fatty acid is present in the form of fish oil containing 33% DHA and 23% EPA (calculated on the total weight of fish oil). ! 6. The composition according to claim 1 or 2, which has the following composition:! beta-carotene 2 mg (3344 ME); (+/- 20%) ascorbic acid 60 mg; (+/- 20%) Vitamin E10 mg (10 ME); (+/- 20%) zinc gluconate 15 mg; (+/- 20%) sodium selenite 50 mcg; (+/- 20%) chromium (III) hexahydrate trichloride 25 mcg; (+/- 20%) lutein (pure Flora Glo product) 6 mg; (+/- 20%) fish oil (33% eicosapentanoic acid (EPA): 23% 200 mg; (+/- 20%) docohexanoic acid (DHA))! where the amount is given in the form of wt.% in terms of the total weight of the composition. ! 7. The composition according to claim 6, from which beta-carotene is excluded. ! 8. The composition according to claims 1 and 2, in which zinc is present in the form of zinc oxide. ! 9. The composition according to one of claims 1 and 2, which is part of one, two, three or more tablets. ! 10. The use of the composition according to claims 1 to 9 for the preparation of a medicinal product intended for the treatment and / or prevention of age-related macular degeneration or any other pathological retinal disorder. ! 11. Method of treatment and / or warning

Claims (12)

1. Композиция, содержащая1. A composition comprising примерно от 10 до 150 мг витамина С,about 10 to 150 mg of vitamin C, примерно от 5 до 30 мг витамина Е,about 5 to 30 mg of vitamin E, примерно от 1 до 20 мг лютеина,about 1 to 20 mg of lutein, примерно от 5 до 30 мг цинка,about 5 to 30 mg of zinc, примерно от 15 до 150 мкг селена,about 15 to 150 micrograms of selenium, примерно от 5 до 75 мкг хрома иabout 5 to 75 micrograms of chromium and примерно от 10 до 600 мг омега-3-жирной кислоты.from about 10 to 600 mg of omega-3 fatty acid. 2. Композиция по п.1, дополнительно содержащая примерно от 0,5 до 6 мг бета-каротина.2. The composition according to claim 1, additionally containing from about 0.5 to 6 mg beta-carotene. 3. Композиция по пп.1 и 2, в которой витамин С присутствует в виде аскорбиновой кислоты, натрия аскорбата или их смеси.3. The composition according to claims 1 and 2, in which vitamin C is present in the form of ascorbic acid, sodium ascorbate, or a mixture thereof. 4. Композиция по пп.1 и 2, в которой витамин Е присутствует в виде DL-альфа-токоферола ацетата.4. The composition according to claims 1 and 2, in which vitamin E is present in the form of DL-alpha-tocopherol acetate. 5. Композиция по пп.1 и 2, в которой омега-3-жирная кислота присутствует в виде рыбьего жира, содержащего 33% ДГК и 23% ЭПК (в пересчете на общую массу рыбьего жира).5. The composition according to claims 1 and 2, in which the omega-3 fatty acid is present in the form of fish oil containing 33% DHA and 23% EPA (in terms of the total weight of fish oil). 6. Композиция по п.1 или 2, которая имеет следующий состав:6. The composition according to claim 1 or 2, which has the following composition: бета-каротинbeta carotene 2 мг (3344 ME); (+/- 20%)2 mg (3344 ME); (+/- 20%) аскорбиновая кислотаvitamin C 60 мг; (+/- 20%)60 mg; (+/- 20%) витамин Еvitamin e 10 мг (10 ME); (+/-20%)10 mg (10 ME); (+/- 20%) цинка глюконатzinc gluconate 15 мг; (+/-20%)15 mg; (+/- 20%) натрия селенитsodium selenite 50 мкг; (+/- 20%)50 mcg; (+/- 20%) гексагидрат хрома(III) трихлоридаchromium (III) trichloride hexahydrate 25 мкг; (+/- 20%)25 mcg; (+/- 20%) лютеин (чистый продукт Flora Glo)lutein (pure Flora Glo product) 6 мг; (+/- 20%)6 mg; (+/- 20%) рыбий жир (33% эйкозапентановой кислоты (ЭПК): 23%fish oil (33% eicosapentanoic acid (EPA): 23% 200 мг; (+/- 20%)200 mg; (+/- 20%) докогексановой кислоты (ДГК))docohexanoic acid (DHA))  
где количества даны в виде мас.% в пересчете на общую массу композиции.where the amount is given in the form of wt.% in terms of the total weight of the composition. 7. Композиция по п.6, из которой исключен бета-каротин.7. The composition according to claim 6, from which beta-carotene is excluded. 8. Композиция по пп.1 и 2, в которой цинк присутствует в виде цинка оксида.8. The composition according to claims 1 and 2, in which zinc is present in the form of zinc oxide. 9. Композиция по одному из пп.1 и 2, которая входит в состав одной, двух, трех или большего количества таблеток.9. The composition according to one of claims 1 and 2, which is part of one, two, three or more tablets. 10. Применение композиции по пп.1-9 для приготовления лекарственного средства, предназначенного для лечения и/или предупреждения связанной с возрастом дегенерации желтого пятна или любого другого патологического нарушения сетчатки.10. The use of a composition according to claims 1 to 9 for the preparation of a medicament for the treatment and / or prevention of age-related macular degeneration or any other pathological retinal disorder. 11. Способ лечения и/или предупреждения связанной с возрастом дегенерации желтого пятна или любого другого патологического нарушения сетчатки у индивидуума, заключающийся в том, что вводят композицию по одному из пп.1-9 в эффективном количестве.11. A method of treating and / or preventing age-related macular degeneration or any other pathological retinal disorder in an individual, comprising administering the composition according to one of claims 1 to 9 in an effective amount. 12. Способ по п.11, в котором композицию вводят оральным путем.12. The method according to claim 11, in which the composition is administered orally.
RU2007137988/15A 2005-03-16 2006-03-14 VITAMIN MIXES RU2007137988A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502582A FR2883182B1 (en) 2005-03-16 2005-03-16 VITAMIN COMPOSITION USEFUL IN THE TREATMENT OF OCULAR DISEASES
FR0502582 2005-03-16

Publications (1)

Publication Number Publication Date
RU2007137988A true RU2007137988A (en) 2009-04-27

Family

ID=35159734

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007137988/15A RU2007137988A (en) 2005-03-16 2006-03-14 VITAMIN MIXES

Country Status (11)

Country Link
EP (1) EP1865948A1 (en)
JP (1) JP2008533075A (en)
KR (1) KR20070112389A (en)
CN (1) CN101132790A (en)
AU (2) AU2006224771A1 (en)
BR (1) BRPI0608512A2 (en)
CA (1) CA2599468A1 (en)
FR (1) FR2883182B1 (en)
MX (1) MX2007011315A (en)
RU (1) RU2007137988A (en)
WO (1) WO2006097267A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101262855A (en) * 2005-09-08 2008-09-10 帝斯曼知识产权资产管理有限公司 Method of treatment or prevention of age-related macular degeneration
JP2008239528A (en) * 2007-03-26 2008-10-09 Lion Corp Eye and brain function improver
WO2009098186A1 (en) * 2008-02-04 2009-08-13 Novartis Ag Organic compounds
WO2011095837A1 (en) * 2010-02-02 2011-08-11 Soluciones Extractivas Alimentarias, S.L. Solutex Docosahexaenoic acid ethyl esters and/or its derivatives for prevention and/or treatment of age-related macular degeneration
CN102726734A (en) * 2012-07-12 2012-10-17 邓群洲 Soft capsule rich in xanthophylls and multiple vitamins and preparation method of soft capsule
CN108495621A (en) * 2016-01-15 2018-09-04 诺维克斯科技私人有限公司 Stablize agreeable to the taste vitamin C and zinc contains tablet composition
CN110559314A (en) * 2018-05-17 2019-12-13 中港大富科技有限公司 Composition for protecting eyesight
FR3094209B1 (en) * 2019-03-25 2021-03-12 Sophie Hvostoff COMPOSITION OF DESMODIUM AND TRIVALENT CHROME AND USE AT EYE VIEW
CN111943268A (en) * 2020-08-19 2020-11-17 成都虹冉生物科技有限公司 Process for recovering chromium from waste liquid generated in production of vitamin K3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
US6582721B1 (en) * 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
AU2002221934A1 (en) * 2000-12-16 2002-06-24 Aventis Pharma Deutschland Gmbh Health promoting compositions
EP1214893A1 (en) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Health promoting compositions
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
AU2004249256A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of AMD with combination of ingredients

Also Published As

Publication number Publication date
JP2008533075A (en) 2008-08-21
CA2599468A1 (en) 2006-09-21
AU2006224771A1 (en) 2006-09-21
KR20070112389A (en) 2007-11-23
WO2006097267A1 (en) 2006-09-21
AU2010201804A1 (en) 2010-05-27
EP1865948A1 (en) 2007-12-19
CN101132790A (en) 2008-02-27
BRPI0608512A2 (en) 2010-01-05
FR2883182A1 (en) 2006-09-22
MX2007011315A (en) 2007-11-08
FR2883182B1 (en) 2008-02-15

Similar Documents

Publication Publication Date Title
RU2007137988A (en) VITAMIN MIXES
EP1516542B1 (en) Nutritional supplement to treat macular degeneration
US7267830B2 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
US20100028459A1 (en) Nutritional supplement composition for treatment of ocular diseases
US20100068298A1 (en) Nutritional supplement composition for treatment of ocular diseases
US20100159029A1 (en) Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
WO2009098186A1 (en) Organic compounds
US12076358B2 (en) Composition of desmodium and trivalent chromium, and ocular use
HK1061954B (en) Nutritional supplement to treat macular degeneration
HK1068520A (en) Nutritional supplement to treat macular degeneration
HK1076991B (en) Nutritional supplement to treat macular degeneration
AU2002258562A1 (en) Nutritionaln supplement to treat macular degeneration

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100729